Direct Answer
McKesson Corporation reports revenue across 4 business segments in its fiscal 2026 Form 10-K. North American Pharmaceutical is the largest, with $337 billion of revenue (83% of the total), followed by Oncology and Multispecialty at $48.4 billion (12%).
How Does McKesson Corporation Make Money?
North American Pharmaceutical supplies 83% of revenue, so McKesson Corporation's results move mostly with that one business; the others matter more for diversification than for the headline number. Between fiscal 2025 and 2026, Oncology and Multispecialty grew fastest (+31.4%) and Medical Surgical Solutions slowest (+1.1%), so the revenue mix tilts toward Oncology and Multispecialty while that gap lasts.
| Segment | FY2026 revenue | FY2025 revenue | Share of revenue | Change |
|---|---|---|---|---|
| North American Pharmaceutical | $337 billion | $305 billion | 83.4% | 10.6% |
| Oncology and Multispecialty | $48.4 billion | $36.9 billion | 12.0% | 31.4% |
| Medical Surgical Solutions | $11.5 billion | $11.4 billion | 2.9% | 1.1% |
| Prescription Technology Solutions | $5.8 billion | $5.2 billion | 1.4% | 11.3% |
What the Segment Figures Do Not Show
The rows above add up to 100% of McKesson Corporation's reported revenue for fiscal 2026; the difference is intersegment eliminations, corporate revenue or items the company reports outside its segments. Segment definitions are management's choice and change when a company reorganizes, in which case it restates prior years in the next filing, so a multi-year comparison should use the figures from a single filing. Revenue shows where sales come from, not where profit or cash is earned: a small segment can carry most of the margin.
Where These Numbers Come From
Every figure on this page is a value McKesson Corporation reported in the segment note and revenue disclosures of its Form 10-K filed May 8, 2026 (accession 0000927653-26-000069), read from the SEC's Financial Statement Data Sets. The prior-year column is the comparative figure from that same filing, so it reflects any restatement for a change in segments. Category names are the company's own XBRL labels, lightly reformatted for reading.
Rows that only total other rows (for example a "Products" line beside the individual products) are left out so nothing is counted twice. This page is educational and describes reported history for fiscal 2026; it is not a forecast or a recommendation.
Frequently Asked Questions
What are McKesson Corporation's business segments?
In its fiscal 2026 Form 10-K, McKesson Corporation reports revenue for North American Pharmaceutical, Oncology and Multispecialty, Medical Surgical Solutions and Prescription Technology Solutions.
Which part of McKesson Corporation brings in the most revenue?
North American Pharmaceutical, with $337 billion of revenue in fiscal 2026, or 83% of the total.
Where does McKesson Corporation report its segment results?
In the segment note to the financial statements in its Form 10-K, most recently filed May 8, 2026, alongside management's discussion of each segment's results.